Home Insights Assessment and Prioritization of Attractive IO Targets

Assessment and Prioritization of Attractive IO Targets

Less than 1 min read
Case StudiesAsset Value CreationStrategyValue, Pricing & Access

A global pharma company approached SmartAnalyst to evaluate the market and help it make strategic choices for acquiring its next immuno-oncology (IO) targets.

SmartAnalyst conducted secondary research and its depth of experience in IO to shortlist 25 targets for evaluation and prioritization, based on client-specific parameters, including biological rationale, scientific evidence, commercial considerations, and potential combinability of select targets with other novel IO targets.

SmartAnalyst identified the five most attractive IO targets through a close analysis of key indicators that helped the company to frame its strategic acquisitions.

Read the full case study here.